Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP

Allworth Financial LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 322.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,736 shares of the biopharmaceutical company’s stock after purchasing an additional 30,331 shares during the period. Allworth Financial LP’s holdings in Halozyme Therapeutics were worth $2,914,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. DLD Asset Management LP bought a new stake in shares of Halozyme Therapeutics in the second quarter worth $650,250,000. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 127.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Federated Hermes Inc. raised its stake in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after buying an additional 1,082,638 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in Halozyme Therapeutics during the third quarter valued at approximately $77,587,000. Finally, Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $51,295,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $63.43 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $82.22. The company has a market cap of $7.49 billion, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 0.26 and a beta of 0.98. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The firm has a fifty day moving average of $71.53 and a 200-day moving average of $70.20.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The firm had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 earnings per share. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HALO. Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $78.56.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total value of $702,100.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,905,833.80. This trade represents a 1.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 90,857 shares of company stock valued at $6,500,287 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.